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Abstract
Malignant pleural effusion (MPE) is common with mesothelioma. We
report two cases of extraordinarily viscous MPEs associated with mesothelioma. The viscosity prohibited spontaneous gravity-dependent drainage via
indwelling pleural catheters. Our ex vivo experiments found very high
hyaluronic acid (HA) content within the ﬂuid. Treatment of the ﬂuid with
hyaluronidase, but not with deoxyribonucleases, signiﬁcantly reduced ﬂuid
viscosity. The results provide proof that HA can contribute to high viscosity
of pleural ﬂuid in mesothelioma. Research into strategies of counteracting
HA properties in the management of MPEs may provide further insight.
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Introduction
Pleural effusions affect over 90% of patients with malignant
pleural mesothelioma. The malignant pleural effusion
(MPE) commonly appears serosanguinous or haemorrhagic,
and can be evacuated using a range of devices, such as aspiration needles, chest tube, or indwelling pleural catheter
(IPC). We report two cases of extraordinarily viscous MPEs
in mesothelioma patients. Our ex vivo experiments attributed the viscosity to the high hyaluronic acid (HA) content
within the ﬂuid, which could be signiﬁcantly reduced with
hyaluronidase.

Case Report
Patient 1
A 79-year-old man presented with a left-sided pleural effusion which was noted as viscous on the initial therapeutic
aspiration. Cytology conﬁrmed malignant mesothelioma.

Upon recurrence of the MPE, an IPC (Rocket, UK) was
inserted but the thick ﬂuid prohibited spontaneous drainage. He was referred to our centre for further management.
The ﬂuid was partially evacuated by connecting the IPC
via a connector to a 60-mL syringe through which manual
suction could be applied. The viscosity of the ﬂuid prohibited usual laboratory biochemical analyses of the ﬂuid. In
an attempt to reduce ﬂuid viscosity to clear the remaining
ﬂuid, two doses of 5 mg of deoxyribonuclease (DNase) was
instilled over two days via the IPC, after which ~300 and
~200 mL of ﬂuid were drained. The underlying lung reexpanded on chest X-ray (CXR) and talc slurry pleurodesis
was administered via the IPC.
Unfortunately, the ﬂuid recurred over the next four
weeks, resulting in a large multiloculated effusion associated with breathlessness and fatigue (Fig. 1A), necessitating
hospitalization. Drainage via the IPC remained difﬁcult
because of the ﬂuid viscosity. Four doses of intrapleural
tissue plasminogen activator (tPA) 2.5 mg and DNase
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Figure 1. The viscous ﬂuid of Patient 1 made drainage via indwelling pleural catheter (IPC) difﬁcult, resulting in large loculated collections of pleural
ﬂuid, requiring hospital admission. The chest radiograph (A) showed almost complete opaciﬁcation of the left hemi-thorax which cleared with
intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) therapy (B). However, the beneﬁt was short-lived and signiﬁcant reaccumulation of ﬂuid was shown on his radiograph two weeks later (C). Further treatment with escalated doses of tPA/DNase failed to produce a
response (D).

5 mg were administered twice daily with good effect. A
ﬂuid sample was collected after the ﬁrst dose (Sample 1)
for viscosity and cytological analyses (Tables 1, 2 and
Fig. 2, respectively). A total of 2.8 L of ﬂuid was drained
with signiﬁcant radiographic improvement (Fig. 1B). However, the beneﬁt was short-lived and ﬂuid re-accumulated
within two weeks (Fig. 1C), during which time he received
one cycle of treatment in an immunotherapy trial. A further attempt with tPA 2.5 mg/DNase 5 mg given in outpatient clinic produced only marginal beneﬁt. With strong
manual suction via the IPC, 380 mL of viscous ﬂuid was
aspirated and a further 350 mL was drained the next day.
Nonetheless, a massive residual effusion remained.
The patient was readmitted two weeks later for ongoing
difﬁculty with IPC drainage (<100 mL each attempt)
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(Fig. 1D). Sample 2 was collected for viscosity analyses
(Table 1). During the hospitalization, he received
intrapleural tPA 5 mg/DNase 5 mg and suction via the
IPC with little effect (60 and 275 mL after the ﬁrst two
doses). A further attempt using tPA 10 mg and DNase
10 mg yielded 200 mL and minimal radiographic improvement. He was discharged and died seven months later
from his mesothelioma.

Patient 2
A 79-year-old female presenting with a right pleural effusion underwent video-assisted thoracoscopic pleural biopsy
(which showed mesothelioma) and talc poudrage. The
ﬂuid recurred after surgery necessitating a therapeutic
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Table 1. Pleural ﬂuid HA concentrations and viscosity levels (mPas) of pleural ﬂuid after incubation with
hyaluronidase (U/mL).

Fluid viscosity (mPas) after treatment with different concentrations
of hyaluronidase (U/mL)
HA concentration in pleural ﬂuid
Patient 1
(Sample 1)
Patient 1
(Sample 2)
Patient 2
(Sample 3)

0

1

10

100

2.66×10 ng/mL

800.21

54.62

21.91

2.94

5.39×106 ng/mL

Too viscous

Too viscous

153.67

18.61

2.31×106 ng/mL

303.03

168.01

6.59

2.87

6

The two samples from Patient 1 were taken about 38 days apart.
HA, hyaluronic acid.

Table 2. Pleural ﬂuid viscosity levels (mPas) of pleural ﬂuid after incubation with rhDNase.

rhDNase (μg/mL)

Patient 1 (Sample 1)

0

2.5

5

10

780.56

690.93

627.61

567.38

Sample 1 was incubated with rhDNase at 2.5, 5, and 10 μg/mL at room temperature for 4 h before viscosity was measured. The range of concentration selected was to approximate the concentration of enzyme in a patient with a 1.5-L pleural effusion treated with 5 mg of rhDNase.
rhDNase, recombinant human deoxyribonuclease.

aspirate which revealed extremely thick exudative pleural
ﬂuid. She underwent regular therapeutic aspiration in an
outside hospital for her MPE over the next four years
(during which time she received various systemic therapy)
before she was referred to our centre for IPC insertion.
The ﬂuid was described as thick and “jelly-like” and failed
to drain via the IPC. Manual suction via the IPC (Rocket)
was required for complete evacuation of the ﬂuid. Talc
slurry was administered after lung re-expansion but the
pleurodesis failed.
For the following 12 months, drainage was performed
(roughly once weekly) via IPC. Sample 3 showed a typical specimen. Standard IPC suction bottles were ineffective to clear the thick ﬂuid. Hence, the patient’s carers
were taught to perform IPC drainage using manual
suction.
After one year, IPC drainage failed despite the abovementioned measures causing signiﬁcant breathlessness
necessitating a hospital admission. A trial of
intrapleural tPA 2.5 mg/DNase 5 mg was successful and
drained 1.5 L with signiﬁcant radiographic clearance.
Regular IPC drainage was re-established. Her mesothelioma continued to progress and she died 10 months
later.

Fluid Viscosity and HA Analyses
Pleural ﬂuid viscosity was determined as described by
Simpson et al. [1]. HA concentrations were determined in
the MPE supernatant using a commercially available HA
binding assay (Corgenix, USA). To test the contribution of
HA to the viscosity of the effusion, samples were incubated
at room temperature for 10 min with hyaluronidase type
V (0–100 U/mL) diluted in phosphate-buffered saline
(both Sigma-Aldrich, USA). To model the effects of
recombinant human DNase (rhDNase) treatment, the
original pleural effusion sample was incubated in the laboratory with rhDNase (Pulmozyme®; Roche, USA) diluted
in normal saline (Baxter, Australia) for 4 h before viscosity
measurement.
We found that MPE from both patients had very high
pleural ﬂuid HA concentrations. Hyaluronidase, but not
rhDNase, was effective in reducing the viscosity of the
ﬂuid in a dose-dependent manner (Tables 1, 2, Video S1).

Discussion
We described two mesothelioma patients with HA-rich
and extremely viscous MPE, limiting ﬂuid drainage. Our

© 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd
on behalf of The Asian Paciﬁc Society of Respirology

3

Hyaluronan in mesothelioma effusion

H.M. Cheah et al.

Figure 2. The cytology sample from Patient 1 demonstrated material
consistent with hyaluronic acid (HA) both in intracellular and extracellular locations. The smear of the viscous pleural ﬂuid (A) shows prominent extracellular granular material within the background consistent
with HA (Diff-Quick stain, original magniﬁcation, 10×). The cell block
(B) of the same pleural ﬂuid demonstrates malignant mesothelioma
cells with prominent intracytoplasmic vacuoles containing eosinophilic
material either with a globular appearance or an appearance similar to
that of crinkled paper, both of which suggest the presence of
hyaluronan (haematoxylin and eosin, original magniﬁcation, 40×).

values [2]. Our experiments provide proof to the long suspicion that HA is involved in generating high viscosity
in MPE.
HA is a long polymer of disaccharides up to 20,000 kDa
in size produced by hyaluronan synthases, present in
abundance in extracellular matrix. It can promote inﬂammation and angiogenesis—processes involved in MPE formation. HA is approved as intra-articular treatment for
osteoarthritis and for use in ophthalmologic conditions. It
is also a common ingredient in skin care products [3].
HA can be degraded by hyaluronidases, a family of
enzymes, and by various non-enzymatic reactions
(e.g. acidic/alkaline hydrolysis) [4]. Hyaluronidases have
been used in low doses in various conditions, mainly to
breakdown extracellular matrix and enhance drug distribution [5,6]. Whether it can be safely applied intrapleurally
and in sufﬁcient therapeutic quantity to lyse HA in human
MPE will need to be investigated.
At present, clinically available options for viscous MPE
are limited. Use of tPA/DNase enhanced the evacuation of
thick infected pleural ﬂuid in clinical trials. The regime
provided some short-term beneﬁts in Patient 1, but subsequent administration did not prove effective. Our ex vivo
experiments did not ﬁnd a major role of rhDNase in
reducing the viscosity. As tPA is known to stimulate significant production of pleural ﬂuid in healthy and diseased
pleura, it is possible that the dilutional effect of this ﬂuid
formation helped with initial drainages. Whether tPA itself
affects viscosity of MPE is unknown.
The composition of pleural ﬂuid may be important to
provide an informed clinical decision to ascertain an effective therapy for pleural effusion management. In cases of
viscous ﬂuid and high HA levels, strategies to counteract
HA production or enhance its breakdown warrant
exploration.

Disclosure Statement
Appropriate written informed consent was obtained for
publication of this case report and accompanying images.

laboratory work conﬁrmed that HA, present in high concentrations in these ﬂuids, likely contributed to the high
viscosity which could be signiﬁcantly reduced using
hyaluronidase.
MPE from mesothelioma contains a vast number of
important mediators. Mesothelioma has been known to
express HA for over 80 years and HA pleural ﬂuid concentrations are a valuable ancillary test for diagnosis. In our
previous study including 96 mesothelioma patients, the
pleural ﬂuid HA level has an area under the curve of 0.89
in its diagnostic value of mesothelioma, highly comparable
with mesothelin. Pleural ﬂuid HA has also prognostic
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
http://onlinelibrary.wiley.com/doi/10.1002/rcr2.694/
suppinfo.
Video S1. Highly viscous pleural ﬂuid from Patient
1 (Sample 2) in the tube labelled untreated is shown.
Treatment of the same sample with hyaluronidase
(100 U/mL for 10 min) signiﬁcantly reduced the ﬂuid
viscosity as shown in the tube labelled treated.
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